These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 30955221)

  • 1. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
    Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
    Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes.
    Gibb FW; McKnight JA; Clarke C; Strachan MWJ
    Diabetologia; 2020 May; 63(5):906-914. PubMed ID: 32034440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.
    Hope SV; Knight BA; Shields BM; Hill AV; Choudhary P; Strain WD; McDonald TJ; Jones AG
    Diabetologia; 2018 Jan; 61(1):66-74. PubMed ID: 28983693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic hypoglycaemia in Type 1 diabetes: incidence and risk factors.
    Henriksen MM; Andersen HU; Thorsteinsson B; Pedersen-Bjergaard U
    Diabet Med; 2019 Jan; 36(1):62-69. PubMed ID: 30368899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential associations of risk factors with severe and non-severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin-treated type 1 diabetes and type 2 diabetes.
    He Y; Kunutsor SK; Kingsnorth AP; Gillies C; Choudhary P; Khunti K; Zaccardi F
    Diabetes Obes Metab; 2024 Aug; 26(8):3361-3370. PubMed ID: 38826105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients.
    Ajjan RA; Abougila K; Bellary S; Collier A; Franke B; Jude EB; Rayman G; Robinson A; Singh BM
    Diab Vasc Dis Res; 2016 May; 13(3):211-9. PubMed ID: 27000105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes.
    Buckingham B; Cheng P; Beck RW; Kollman C; Ruedy KJ; Weinzimer SA; Slover R; Bremer AA; Fuqua J; Tamborlane W;
    Diabetologia; 2015 Jun; 58(6):1167-74. PubMed ID: 25773405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
    Pinckney A; Rigby MR; Keyes-Elstein L; Soppe CL; Nepom GT; Ehlers MR
    Clin Ther; 2016 Jun; 38(6):1327-1339. PubMed ID: 27209482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High intensity interval training as a novel treatment for impaired awareness of hypoglycaemia in people with type 1 diabetes (HIT4HYPOS): a randomised parallel-group study.
    Farrell CM; McNeilly AD; Hapca S; Fournier PA; Jones TW; Facchinetti A; Cappon G; West DJ; McCrimmon RJ
    Diabetologia; 2024 Feb; 67(2):392-402. PubMed ID: 38010533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.
    Charleer S; De Block C; Nobels F; Radermecker RP; Lowyck I; Mullens A; Scarnière D; Spincemaille K; Strivay M; Weber E; Taes Y; Vercammen C; Keymeulen B; Mathieu C; Gillard P;
    Diabetes Care; 2020 Dec; 43(12):3016-3023. PubMed ID: 33067260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).
    Ólafsdóttir AF; Bolinder J; Heise T; Polonsky W; Ekelund M; Wijkman M; Pivodic A; Ahlén E; Schwarcz E; Nyström T; Hellman J; Hirsch IB; Lind M
    Diabetes Obes Metab; 2021 Feb; 23(2):619-630. PubMed ID: 33200487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of severe hypoglycaemia in pregnant women with type 1 diabetes mellitus can be reduced with unchanged HbA1c levels and pregnancy outcomes in a routine care setting.
    Ringholm L; Secher AL; Pedersen-Bjergaard U; Thorsteinsson B; Andersen HU; Damm P; Mathiesen ER
    Diabetes Res Clin Pract; 2013 Aug; 101(2):123-30. PubMed ID: 23820486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
    Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
    Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between recent exposure to continuous glucose monitoring-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes.
    Svensson CH; Fabricius TW; Verhulst CEM; Kristensen PL; Tack CJ; Heller SR; Amiel SA; McCrimmon RJ; Evans M; Holst JJ; de Galan BE; Pedersen-Bjergaard U;
    Diabetes Obes Metab; 2024 Aug; 26(8):3213-3222. PubMed ID: 38774963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.